Browsing by Author "Madrid Arenas, Jorge"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability
    (2020) Pinto Paganini, Mauricio Arturo; Bravo Castillo, Maria Loreto; Sánchez Rojel, César Giovanni; Acevedo, Francisco; Mondaca Contreras, Sebastián Patricio; Ibañez, Carolina; Galindo A., Héctor; Madrid Arenas, Jorge; Nervi Nattero, Bruno; Peña Durán, José Esteban; Torres Montes, Paula Javiera; Owen, Gareth Ivor; Corvalán R., Alejandro; Garrido S., Marcelo; Córdova Delgado, M.; Retamal, I. N.; Muñoz Medel, M.; Durán, D.; Villanueva, F.; Koch, E.; Armisen, R.
  • Thumbnail Image
    Item
    Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
    (2013) Galindo, J.; Gabrielli Nervi, Mauricio; Guerra, J. F.; Cassina, J. C.; Garrido, M.; Jarufe Cassis, Nicolás; Borghero Ríos, Yerko Orestes; Madrid Arenas, Jorge; Zoroquiain Vélez, José Pablo; Roa Strauch, Juan Carlos Enrique; Martínez, J.
  • Thumbnail Image
    Item
    Reduction in the number of early melanomas diagnosed during the COVID‐19 pandemic: a single‐centre cohort study
    (2021) Koch Hein, Erica Cristina; Villanueva, Francisco; Marchetti, Michael A.; Abarzúa Araya, Álvaro Rodrigo; Cárdenas de la Torre, Consuelo Paz; Castro, Juan Camilo; Domínguez Covarrubias, Francisco José; Droppelmann, Katherine; Droppelmann, Nicolás; Galindo A., Héctor; León Ramírez, Augusto; Madrid Arenas, Jorge; Molgó Novell, Montserrat; Mondaca, Sebastián; Montero, Pablo H.; Uribe González, Pablo Francisco; Villaseca, Miguel A.; Vinés Vásquez, Eugenio; Navarrete Dechent, Cristian
  • Thumbnail Image
    Item
    Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación
    (2013) Acevedo Claros, Francisco Nicolás; Herrera Nieda, Maria Elisa; Madrid Arenas, Jorge; Sánchez Rojel, César Giovanni
    Neoadjuvant chemotherapy is an accepted strategyforpatients with locally advanced breast cáncer. This approach increases the possibilities ofconservative treatment and improves the resectability rates ofinitially unresectable tumors. In addition, preoperative systemic therapy allows the evaluation of prognostic and predictive factors, dynamically and in vivo. Since over 80% ofthese tumors express estrogen receptors (ER), endocrine therapy seems a logical treatment to employ in the neoadjuvant setting. The advent ofnew drugs that regúlate the ERfunction, along with the results of severa! clinical studies with the use of neoadjuvant endocrine therapy, support the feasibility and safety of utilizing this strategy before surgery. We herein analyze the available clinical evidence about the use of neoadjuvant therapy aiming to regúlate the activity ofthe ER. We also discuss the valué of predictive factors that could help the oncologist to select those patients most likely to benefit from this approach and the role of endocrine therapy as a research instrument.